Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: A systemic review and meta-analysis

Cao, Zhifei; Bao, Meimei; Miele, Lucio; Sarkar, Fazlul H.; Wang, Zhiwei; Zhou, Quansheng

doi:10.1016/j.ejca.2013.07.148

Cited by 202 publications

(165 citation statements)

References 58 publications

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…If the study did not provide the HR but reported the survival curve, survival rates at specified times were extracted to reconstruct the HR estimate and its variance, with the assumption that the rate of patients censored was constant during the follow-up (Tierney et al, 2007). Survival rates on the graphical representation of the survival curves were read by Engauge Digitizer version 2.5 (Cao et al, 2013). Quality assessment of the cohort studies was performed using the NOS (Wells et al, 2012).…”

Section: Data Extraction and Quality Assessmentmentioning

confidence: 99%

Prognostic Role of Hepatoma-derived Growth Factor in Solid Tumors of Eastern Asia: a Systematic Review and Meta-Analysis

Bao

Liu²,

Wang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Hepatoma-derived growth factor (HDGF) is a novel jack-of-all-trades in cancer. Here we quantify the prognostic impact of this biomarker and assess how consistent is its expression in solid tumors. A comprehensive search strategy was used to search relevant literature updated on October 3, 2014 in PubMed, EMBASE and WEB of Science. Correlations between HDGF expression and clinicopathological features or cancer prognosis was analyzed. All pooled HRs or ORs were derived from random-effects models. Twenty-six studies, primarily in Eastern Asia, covering 2,803 patients were included in the analysis, all of them published during the past decade. We found that HDGF overexpression was significantly associated with overall survival (

show abstract

Section: Data Extraction and Quality Assessmentmentioning

confidence: 99%

Prognostic Role of Hepatoma-derived Growth Factor in Solid Tumors of Eastern Asia: a Systematic Review and Meta-Analysis

Bao

Liu²,

Wang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Meta-analysis results of Cao and co-workers [8] indicate that VM phenomenon is present in different degree in certain types of tumors. Percentage contribution of VM in different tumors is summarized in the figure 3.…”

Section: Vasculogenic Mimicry Of Tumorsmentioning

confidence: 99%

“…In NSCLC, vasculogenic mimicry is characteristic for early stages of tumor (T1 7.1%, T2 57.1%), and with tumor progression, the percentage of VM is decreased (T3 19.1%, T4 16.7%) [55]. However, from meta-analysis of Cao and co-workers [8] it is known that metastatic tumors show higher VM content (45.3%), in comparison to non-invasive (22.6%). Independently of these differences, VM is always connected with high potential to metastasis and is a poor prognostic factor [6].…”

Section: Vasculogenic Mimicry Of Tumorsmentioning

confidence: 99%

“…An increase of VM density is connected with the increase of PGCCs amount. [10,57,92] mechanism of formation independent of VEGF, EMT contribution [52,54,57,81] interaction with ECM increase of MMPs activity and ECM remodeling [50,60] phenotype/ cell plasticity expression of stem cell multipotent phenotype (Sox-2, TWIST-1, CD133/CD44) with ability to ECs differentiation at the same time [46,68,74,84,85] tumor invasiveness and metastasis high tumor progresion and aggressiveness [50,63] prognosis for patient adverse prognostic factor, shorter survival of patient [8,50,51] Final classification of vessel-like structures needs usually more studies towards amplification of EGFR gene, which is often observed in tumor cells derived from epithelial tissue [26].…”

Section: Vasculogenic Mimicry Of Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

Tumor Blood Vessels and Vasculogenic Mimicry – Current Knowledge and Searching for New Cellular/Molecular Targets of Anti-Angiogenic Therapy

Knopik-Skrocka

Kręplewska

Jarmołowska-Jurczyszyn

2017

Advances in Cell Biology

View full text Add to dashboard Cite

Summary: Blood vessel formation in tumor is defined as tumor angiogenesis. So far, the most known its mechanism is sprouting, which means formation of blood vessels from existing ones, as a result of the proliferation and migration of endothelial cells. The main mitogenic factor of these cells is vascular endothelial growth factor VEGF, acting by VEGFR-2 receptors. Recent studies have provided knowledge about the ability of tumors to form vessel-like structures. The phenomenon was called vascular mimicry. Tumor cells show a high plasticity and they can undergo differentiation to the ones with phenotype similar to endothelial cells. Each of the known tumor angiogenesis mechanisms is a result of many different factors and cell cooperation in tumor microenvironment. Tumor ability to the heterogeneous vascularization forces developing of complex, anti-angiogenic therapy directed to different molecular and cellular targets. Therapies, used so far, often lead to drug-induced hypoxia, which increases tumor cell aggressiveness and metastasis.Keywords: tumor angiogenesis, vasculogenic mimicry, anti-angiogenic strategies, resistance to anti-angiogenic therapy Sprouting angiogenesis -formation via endothelial cells proliferation and migration towards avascular tumor area of new branches of blood vessels Intussusception -formation of blood vessels as a result of intussusception (septum) inside existing blood vessels Co-option -oxygen and nutrients acquire as a result of tumor cells migration along existing blood vessels Vasculogenic mimicry -formation by tumor cells of vessel-like structures, without endothelial cells participation Vasculogenesis -formation of tumor blood vessels de novo, as a result of endothelial progenitor cells recruitment

show abstract

“…Aggressive osteosarcoma cells demonstrate increased angiogenesis and vasculogenic mimicry (7). Several studies have revealed that tumor cells may directly form tumor blood vessels through vasculogenic mimicry (8)(9)(10)(11)(12)(13). This is closely associated with tumor metastasis and the poor prognosis of various cancers, including osteosarcoma (11,12).…”

Section: Introductionmentioning

confidence: 99%

Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma

Zhang

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The high mobility group box 1 (HMGB1) protein functions as an extracellular signaling molecule that is critical in inflammation and carcinogenesis. The HMGB1 protein is actively secreted by natural killer cells, monocytes and macrophages, and acts as an inflammatory cytokine. The present study enrolled 174 patients that underwent a tumorectomy between 2006 and 2013 in Shandong Provincial Hospital. The age of the patients ranged between 13 and 74 years, with a median age of 27 years. The tumors of the patients were staged according to the Union for International Cancer Control 2009 tumor-node-metastasis tumor staging system. Nuclear grading was based on the Fuhrman grading system. In the osteosarcoma tissue samples, HMGB1 expression was detected in 84 samples (48.3%) with a low immunoreactivity and in 90 samples (51.7%) with a high immunoreactivity. The association between clinicopathological characteristics and tumor cell HMGB1 expression (low vs. high) was summarized. The association between HMGB1 expression and tumor size, tumor stage and nuclear grade was statistically significant (P=0.034, 0.008 and 0.019, respectively). There was no significant association between HMGB1 expression and the age of the patients (P= 0.335; Table I). The current study demonstrated that patients with a high HMGB1 expression (>50% cells expressing HMGB1) had poorer survival rates, and therefore a poorer prognosis, compared with patients with low HMGB1 immunostaining (10-50% cells expressing HMGB1). The results of the present study suggest that higher expression levels of HMGB1 are significantly associated with a poorer prognosis and may act as a marker for prognosis in osteosarcoma, particularly osteosarcoma recurrence. Additional studies investigating the biological features of HMGB1 may confirm the potential role of HMGB1 as a novel target for anticancer therapy in osteosarcoma.

show abstract

Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: A systemic review and meta-analysis

Cited by 202 publications

References 58 publications

Prognostic Role of Hepatoma-derived Growth Factor in Solid Tumors of Eastern Asia: a Systematic Review and Meta-Analysis

Prognostic Role of Hepatoma-derived Growth Factor in Solid Tumors of Eastern Asia: a Systematic Review and Meta-Analysis

Tumor Blood Vessels and Vasculogenic Mimicry – Current Knowledge and Searching for New Cellular/Molecular Targets of Anti-Angiogenic Therapy

Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma

Contact Info

Product

Resources

About